Archana Shanker and Gitika Suri provide an in-depth look into legal and administrative proceedings for enforcing patent rights against infringers. In addition to a High Court, the Indian
Patients everywhere would benefit from top-down reform to align India’s patent law with global norms say Pravin Anand and Archana Shanker. To protect the IP of innovators and
The information technology sector in India has grown leaps and bounds over the last decade, turning India into a hub for software development and outsourcing. Revenue generated through
Software is too functional to be covered by copyright and too abstract to be embraced by patent law. So how can it be protected? Has the perfect method
Archana Shanker and Devinder Singh Rawat discuss the rise and regulation of biosimilar biologics in the Indian pharmaceutical market. Biologics are an important component of the pharmaceutical industry and
Archana Shanker and Drishi Kaur discuss the often ambiguous requirements of section 8 of the Indian Patents Act. The disclosure of foreign filing to the Indian Patent Office
Ever since its inception, the Intellectual Property Appellate Board has been a catalyst in the evolution of the patent system in the country, discuss Archana Shanker and Neeti
Archana Shanker and Vidisha Garg explore the protection of therapeutic substances used under folk medicine practices as ‘traditional knowledge’ by special provisions of the patent law. In October 2012,
Pravin Anand and Aditya Gupta explain the errors the Controller General of Patents made in granting a compulsory licensing order to Bayer. The affordability of pharmaceuticals has been
Archana Shanker considers the implications of the grant of a compulsory licence for the very first time in the Indian patent system. The licence was granted to Natco
